{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:21:14Z","timestamp":1776475274126,"version":"3.51.2"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1012615","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000}}],"reference-count":76,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20J00868, 21K15453"],"award-info":[{"award-number":["20J00868, 21K15453"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research (KAKENHI) B","award":["18H01139, 16H04845"],"award-info":[{"award-number":["18H01139, 16H04845"]}]},{"name":"Scientific Research (KAKENHI) B","award":["20H03499, 21H02449"],"award-info":[{"award-number":["20H03499, 21H02449"]}]},{"name":"Scientific Research in Innovative Areas","award":["20H05042"],"award-info":[{"award-number":["20H05042"]}]},{"DOI":"10.13039\/501100001700","name":"the Ministry of Education, Culture, Sports, Science, and Technology","doi-asserted-by":"crossref","award":["20K16996"],"award-info":[{"award-number":["20K16996"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AMED Strategic International Brain Science Research Promotion Program","award":["22wm0425011s0302"],"award-info":[{"award-number":["22wm0425011s0302"]}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["JP22dm0307009"],"award-info":[{"award-number":["JP22dm0307009"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AMED CREST","award":["19gm1310002"],"award-info":[{"award-number":["19gm1310002"]}]},{"name":"AMED Development of Vaccines for the Novel Coronavirus Disease","award":["21nf0101638s0201"],"award-info":[{"award-number":["21nf0101638s0201"]}]},{"name":"AMED Japan Program for Infectious Diseases Research and Infrastructure","award":["22wm0325007s8002"],"award-info":[{"award-number":["22wm0325007s8002"]}]},{"name":"AMED Japan Program for Infectious Diseases Research and Infrastructure","award":["22wm0325007j0103"],"award-info":[{"award-number":["22wm0325007j0103"]}]},{"name":"AMED Japan Program for Infectious Diseases Research and Infrastructure","award":["22wm0325007h0001, 22wm0325004s0201, 22wm0325012s0301, 22wm0325015s0301"],"award-info":[{"award-number":["22wm0325007h0001, 22wm0325004s0201, 22wm0325012s0301, 22wm0325015s0301"]}]},{"name":"AMED Research Program on Emerging and Re-emerging Infectious Diseases","award":["21wm0325007s8002"],"award-info":[{"award-number":["21wm0325007s8002"]}]},{"name":"AMED Research Program on Emerging and Re-emerging Infectious Diseases","award":["22fk0108140s0802"],"award-info":[{"award-number":["22fk0108140s0802"]}]},{"name":"AMED Research Program on HIV\/AIDS","award":["22fk0410052s0401"],"award-info":[{"award-number":["22fk0410052s0401"]}]},{"name":"AMED Program for Basic and Clinical Research on Hepatitis","award":["22fk0210094"],"award-info":[{"award-number":["22fk0210094"]}]},{"name":"AMED Program on the Innovative Development and the Application of New Drugs for Hepatitis B","award":["22fk0310504j0001"],"award-info":[{"award-number":["22fk0310504j0001"]}]},{"name":"AMED Program on the Innovative Development and the Application of New Drugs for Hepatitis B","award":["22fk0310504h0501"],"award-info":[{"award-number":["22fk0310504h0501"]}]},{"name":"AMED International Collaborative Research Program Strategic International Collaborative Research Program","award":["22jm0210068j0004"],"award-info":[{"award-number":["22jm0210068j0004"]}]},{"name":"AMED Research Program on Hepatitis","award":["19fk0210036h0502, 19fk0310114h0103"],"award-info":[{"award-number":["19fk0210036h0502, 19fk0310114h0103"]}]},{"name":"AMED Research Program on Hepatitis","award":["19fk0210036j0002, 19fk0310114j0003, 19fk0310103j0203 19fk0310101j1003,"],"award-info":[{"award-number":["19fk0210036j0002, 19fk0310114j0003, 19fk0310103j0203 19fk0310101j1003,"]}]},{"name":"AMED Research Program on Hepatitis","award":["JP23fk0310518"],"award-info":[{"award-number":["JP23fk0310518"]}]},{"DOI":"10.13039\/501100020959","name":"JST-Mirai Program","doi-asserted-by":"publisher","award":["JPMJMI22G1"],"award-info":[{"award-number":["JPMJMI22G1"]}],"id":[{"id":"10.13039\/501100020959","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020959","name":"JST-Mirai Program","doi-asserted-by":"publisher","award":["JPMJMI22G1"],"award-info":[{"award-number":["JPMJMI22G1"]}],"id":[{"id":"10.13039\/501100020959","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020963","name":"Moonshot Research and Development Program","doi-asserted-by":"publisher","award":["JPMJMS2021"],"award-info":[{"award-number":["JPMJMS2021"]}],"id":[{"id":"10.13039\/501100020963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020963","name":"Moonshot Research and Development Program","doi-asserted-by":"publisher","award":["JPMJMS2021, JPMJMS2025"],"award-info":[{"award-number":["JPMJMS2021, JPMJMS2025"]}],"id":[{"id":"10.13039\/501100020963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2022R1C1C2003637"],"award-info":[{"award-number":["2022R1C1C2003637"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health grants","doi-asserted-by":"crossref","award":["R01-OD011095, R01-AI078881, R01-AI116868"],"award-info":[{"award-number":["R01-OD011095, R01-AI078881, R01-AI116868"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004330","name":"Smoking Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"The Takeda Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016289","name":"Taiju Life Social Welfare Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shin-Nihon of Advanced Medical Research"},{"DOI":"10.13039\/501100004298","name":"Secom Science and Technology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004016","name":"The Japan Prize Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004016","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Quantification of intrahepatic covalently closed circular DNA (cccDNA) is a key for evaluating an elimination of hepatitis B virus (HBV) in infected patients. However, quantifying cccDNA requires invasive methods such as a liver biopsy, which makes it impractical to access the dynamics of cccDNA in patients. Although HBV RNA and HBV core-related antigens (HBcrAg) have been proposed as surrogate markers for evaluating cccDNA activity, they do not necessarily estimate the amount of cccDNA. Here, we employed a recently developed multiscale mathematical model describing intra- and intercellular viral propagation and applied it in HBV-infected patients under treatment. We developed a model that can predict intracellular HBV dynamics by use of extracellular viral markers, including HBsAg, HBV DNA, and HBcrAg in peripheral blood. Importantly, the model prediction of the amount of cccDNA in patients over time was confirmed to be well correlated with the data for quantified cccDNA by paired liver biopsy. Thus, our method combining classic and emerging surrogate markers enables us to predict the decay dynamics of cccDNA in patients undergoing treatment.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1012615","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T18:54:36Z","timestamp":1736448876000},"page":"e1012615","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers"],"prefix":"10.1371","volume":"21","author":[{"given":"Kwang Su","family":"Kim","sequence":"first","affiliation":[]},{"given":"Masashi","family":"Iwamoto","sequence":"additional","affiliation":[]},{"given":"Kosaku","family":"Kitagawa","sequence":"additional","affiliation":[]},{"given":"Hyeongki","family":"Park","sequence":"additional","affiliation":[]},{"given":"Sanae","family":"Hayashi","sequence":"additional","affiliation":[]},{"given":"Senko","family":"Tsukuda","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-1824","authenticated-orcid":true,"given":"Takeshi","family":"Matsui","sequence":"additional","affiliation":[]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[]},{"given":"Kentaro","family":"Matsuura","sequence":"additional","affiliation":[]},{"given":"Natthaya","family":"Chuaypen","sequence":"additional","affiliation":[]},{"given":"Pisit","family":"Tangkijvanich","sequence":"additional","affiliation":[]},{"given":"Lena","family":"Allweiss","sequence":"additional","affiliation":[]},{"given":"Takara","family":"Nishiyama","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4798-3660","authenticated-orcid":true,"given":"Naotoshi","family":"Nakamura","sequence":"additional","affiliation":[]},{"given":"Yasuhisa","family":"Fujita","sequence":"additional","affiliation":[]},{"given":"Eiryo","family":"Kawakami","sequence":"additional","affiliation":[]},{"given":"Shinji","family":"Nakaoka","sequence":"additional","affiliation":[]},{"given":"Masamichi","family":"Muramatsu","sequence":"additional","affiliation":[]},{"given":"Kazuyuki","family":"Aihara","sequence":"additional","affiliation":[]},{"given":"Takaji","family":"Wakita","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2455-0002","authenticated-orcid":true,"given":"Alan S.","family":"Perelson","sequence":"additional","affiliation":[]},{"given":"Maura","family":"Dandri","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-9966","authenticated-orcid":true,"given":"Koichi","family":"Watashi","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1780-350X","authenticated-orcid":true,"given":"Shingo","family":"Iwami","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6966","authenticated-orcid":true,"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"issue":"4","key":"pcbi.1012615.ref001","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection","volume":"69","author":"S Liu","year":"2019","journal-title":"Hepatology"},{"issue":"10381","key":"pcbi.1012615.ref002","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B.","volume":"401","author":"WJ Jeng","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"pcbi.1012615.ref003","doi-asserted-by":"crossref","first-page":"a021386","DOI":"10.1101\/cshperspect.a021386","article-title":"Hepadnavirus Genome Replication and Persistence.","volume":"5","author":"J Hu","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"pcbi.1012615.ref004","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"MA Meier","year":"2021","journal-title":"J Hepatol"},{"issue":"10","key":"pcbi.1012615.ref005","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02221-17","article-title":"Relative Abundance of Integrant-Derived Viral RNAs in Infected Tissues Harvested from Chronic Hepatitis B Virus Carriers","volume":"92","author":"N Freitas","year":"2018","journal-title":"J Virol"},{"issue":"4","key":"pcbi.1012615.ref006","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"NA Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"pcbi.1012615.ref007","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/hep.29821","article-title":"Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B","volume":"68","author":"P Lampertico","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"pcbi.1012615.ref008","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger).","volume":"72","author":"M Cornberg","year":"2020","journal-title":"J Hepatol"},{"issue":"7","key":"pcbi.1012615.ref009","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"PA Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"pcbi.1012615.ref010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s12072-009-9140-3","article-title":"HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B.","volume":"3","author":"YF Liaw","year":"2009","journal-title":"Hepatol Int."},{"issue":"3","key":"pcbi.1012615.ref011","doi-asserted-by":"crossref","first-page":"100112","DOI":"10.1016\/j.jhepr.2020.100112","article-title":"Rebound of HBV DNA after cessation of nucleos\/tide analogues in chronic hepatitis B patients with undetectable covalently closed","volume":"2","author":"CL Lai","year":"2020","journal-title":"JHEP Rep"},{"issue":"11","key":"pcbi.1012615.ref012","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure.","volume":"18","author":"GC Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"pcbi.1012615.ref013","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cgh.2007.09.005","article-title":"Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response","volume":"5","author":"HL Chan","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"409","key":"pcbi.1012615.ref014","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"CI Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"issue":"7","key":"pcbi.1012615.ref015","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/liv.13346","article-title":"Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA","volume":"37","author":"DK Wong","year":"2017","journal-title":"Liver Int"},{"issue":"4","key":"pcbi.1012615.ref016","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.","volume":"70","author":"B Testoni","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"pcbi.1012615.ref017","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2893.2003.00437.x","article-title":"Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment","volume":"10","author":"A Rokuhara","year":"2003","journal-title":"J Viral Hepat"},{"key":"pcbi.1012615.ref018","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jcv.2017.12.016","article-title":"Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals","volume":"99\u2013100","author":"H Huang","year":"2018","journal-title":"J Clin Virol"},{"issue":"9","key":"pcbi.1012615.ref019","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/jvh.12908","article-title":"Natural history of serum HBV-RNA in chronic HBV infection","volume":"25","author":"J Wang","year":"2018","journal-title":"J Viral Hepat"},{"issue":"10","key":"pcbi.1012615.ref020","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1128\/JCM.00760-17","article-title":"Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?","volume":"55","author":"Y Gao","year":"2017","journal-title":"J Clin Microbiol"},{"issue":"3","key":"pcbi.1012615.ref021","doi-asserted-by":"crossref","first-page":"e1011238","DOI":"10.1371\/journal.pcbi.1011238","article-title":"Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation to analyze extracellular viral markers.","volume":"20","author":"K Kitagawa","year":"2024","journal-title":"PLoS Comput Biol"},{"issue":"7","key":"pcbi.1012615.ref022","doi-asserted-by":"crossref","first-page":"e3000562","DOI":"10.1371\/journal.pbio.3000562","article-title":"Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma","volume":"18","author":"S Iwanami","year":"2020","journal-title":"PLoS Biol"},{"key":"pcbi.1012615.ref023","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-10-0188-8","volume-title":"Age-structured population dynamics in demography and epidemiology","author":"H. Inaba","year":"2017"},{"issue":"1","key":"pcbi.1012615.ref024","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12876-017-0726-2","article-title":"Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?","volume":"17","author":"S Alonso","year":"2017","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"pcbi.1012615.ref025","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/s41598-021-04022-z","article-title":"An age-structured model of hepatitis B viral infection highlights the potential of different therapeutic strategies.","volume":"12","author":"F Fatehi","year":"2022","journal-title":"Sci Rep."},{"key":"pcbi.1012615.ref026","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coisb.2019.10.003","article-title":"Within-host mathematical models of hepatitis B virus infection: Past, present, and future","volume":"18","author":"A Goyal","year":"2019","journal-title":"Curr Opin Syst Biol"},{"issue":"1","key":"pcbi.1012615.ref027","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0168-8278(02)00115-0","article-title":"Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B","volume":"37","author":"LM Wolters","year":"2002","journal-title":"J Hepatol"},{"issue":"5386","key":"pcbi.1012615.ref028","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"issue":"12","key":"pcbi.1012615.ref029","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1128\/jvi.68.12.8102-8110.1994","article-title":"Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen","volume":"68","author":"H Okamoto","year":"1994","journal-title":"J Virol"},{"issue":"8663","key":"pcbi.1012615.ref030","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0140-6736(89)90713-7","article-title":"Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection","volume":"2","author":"WF Carman","year":"1989","journal-title":"Lancet"},{"issue":"9","key":"pcbi.1012615.ref031","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1128\/jvi.70.9.5845-5851.1996","article-title":"Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication","volume":"70","author":"VE Buckwold","year":"1996","journal-title":"J Virol"},{"issue":"2","key":"pcbi.1012615.ref032","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/135965350601100201","article-title":"A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.","volume":"11","author":"P Colombatto","year":"2006","journal-title":"Antivir Ther"},{"issue":"9","key":"pcbi.1012615.ref033","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1086\/656528","article-title":"Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections","volume":"202","author":"RM Ribeiro","year":"2010","journal-title":"J Infect Dis"},{"issue":"14","key":"pcbi.1012615.ref034","doi-asserted-by":"crossref","first-page":"e0049220","DOI":"10.1128\/JVI.00492-20","article-title":"Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice","volume":"95","author":"V Reinharz","year":"2021","journal-title":"J Virol"},{"issue":"6176","key":"pcbi.1012615.ref035","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"J Lucifora","year":"2014","journal-title":"Science"},{"issue":"6","key":"pcbi.1012615.ref036","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/liv.13046","article-title":"Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B","volume":"36","author":"N Chuaypen","year":"2016","journal-title":"Liver Int"},{"issue":"6","key":"pcbi.1012615.ref037","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jvh.12467","article-title":"A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response","volume":"23","author":"P Tangkijvanich","year":"2016","journal-title":"J Viral Hepat"},{"issue":"12","key":"pcbi.1012615.ref038","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/jvh.12261","article-title":"Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss","volume":"21","author":"Q Zheng","year":"2014","journal-title":"J Viral Hepat"},{"issue":"7","key":"pcbi.1012615.ref039","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"B Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"issue":"3","key":"pcbi.1012615.ref040","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hep.21299","article-title":"Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients","volume":"44","author":"A Laras","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"pcbi.1012615.ref041","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1053\/j.gastro.2007.06.057","article-title":"Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients","volume":"133","author":"T Volz","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"pcbi.1012615.ref042","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B","volume":"66","author":"F Lebosse","year":"2017","journal-title":"J Hepatol"},{"issue":"10","key":"pcbi.1012615.ref043","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Y Tanaka","year":"2009","journal-title":"Nat Genet"},{"issue":"10","key":"pcbi.1012615.ref044","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy","volume":"41","author":"V Suppiah","year":"2009","journal-title":"Nat Genet"},{"issue":"6","key":"pcbi.1012615.ref045","doi-asserted-by":"crossref","DOI":"10.3390\/v13061090","article-title":"Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies.","volume":"13","author":"LA Novotny","year":"2021","journal-title":"Viruses"},{"key":"pcbi.1012615.ref046","article-title":"The scientific basis of combination therapy for chronic hepatitis B functional cure.","author":"SG Lim","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"4","key":"pcbi.1012615.ref047","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.","volume":"70","author":"B Testoni","year":"2019","journal-title":"J Hepatol"},{"issue":"12","key":"pcbi.1012615.ref048","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1128\/JCM.00366-07","article-title":"Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection","volume":"45","author":"DK Wong","year":"2007","journal-title":"J Clin Microbiol"},{"key":"pcbi.1012615.ref049","first-page":"S140","volume-title":"Journal of Hepatology","author":"RMF Yuen","year":"2020"},{"key":"pcbi.1012615.ref050","volume-title":"Late breaking abstract to the AASLD\u2019s The Liver Meeting Digital ExperienceTM 2020","author":"S You","year":"2020"},{"key":"pcbi.1012615.ref051","first-page":"S20","volume-title":"Journal of Hepatology","author":"E Gane","year":"2020"},{"issue":"1","key":"pcbi.1012615.ref052","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.31240","article-title":"Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients","volume":"73","author":"Q Huang","year":"2021","journal-title":"Hepatology"},{"issue":"8","key":"pcbi.1012615.ref053","doi-asserted-by":"crossref","first-page":"e0161978","DOI":"10.1371\/journal.pone.0161978","article-title":"Modelling the Impact of Cell-To-Cell Transmission in Hepatitis B Virus.","volume":"11","author":"A Goyal","year":"2016","journal-title":"PLoS One."},{"key":"pcbi.1012615.ref054","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtbi.2018.06.020","article-title":"The dynamics of integration, viral suppression and cell-cell transmission in the development of occult Hepatitis B virus infection","volume":"455","author":"A Goyal","year":"2018","journal-title":"J Theor Biol"},{"issue":"7","key":"pcbi.1012615.ref055","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"PA Revill","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9959","key":"pcbi.1012615.ref056","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"C Trepo","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"pcbi.1012615.ref057","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12072-016-9745-2","article-title":"Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia.","volume":"10","author":"Q Tian","year":"2016","journal-title":"Hepatol Int"},{"issue":"12","key":"pcbi.1012615.ref058","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1111\/j.1572-0241.2007.01449.x","article-title":"A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"102","author":"RG Gish","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"pcbi.1012615.ref059","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/jmv.25038","article-title":"Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis","volume":"90","author":"L Boglione","year":"2018","journal-title":"J Med Virol"},{"issue":"10","key":"pcbi.1012615.ref060","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/jmv.24013","article-title":"Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B.","volume":"86","author":"X Chen","year":"2014","journal-title":"J Med Virol"},{"issue":"2","key":"pcbi.1012615.ref061","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/gutjnl-2011-301430","article-title":"Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B","volume":"62","author":"P Lampertico","year":"2013","journal-title":"Gut"},{"issue":"1","key":"pcbi.1012615.ref062","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.22586","article-title":"Modeling complex decay profiles of hepatitis B virus during antiviral therapy","volume":"49","author":"H Dahari","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"pcbi.1012615.ref063","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.22744","article-title":"Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients","volume":"49","author":"R Moucari","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"pcbi.1012615.ref064","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/hep.29323","article-title":"Hepatitis B cure: From discovery to regulatory approval","volume":"66","author":"AS Lok","year":"2017","journal-title":"Hepatology"},{"key":"pcbi.1012615.ref065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jtbi.2014.11.020","article-title":"In silico single cell dynamics of hepatitis B virus infection and clearance","volume":"366","author":"JM Murray","year":"2015","journal-title":"J Theor Biol"},{"key":"pcbi.1012615.ref066","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fphys.2020.00146","article-title":"Mathematical Modeling for Hepatitis B Virus: Would Spatial Effects Play a Role and How to Model It?","volume":"11","author":"S Means","year":"2020","journal-title":"Front Physiol."},{"key":"pcbi.1012615.ref067","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jcv.2017.06.009","article-title":"Compartmental HBV evolution and replication in liver and extrahepatic sites after nucleos\/tide analogue therapy in chronic hepatitis B carriers","volume":"94","author":"S Gao","year":"2017","journal-title":"J Clin Virol"},{"issue":"4","key":"pcbi.1012615.ref068","doi-asserted-by":"crossref","first-page":"e1006296","DOI":"10.1371\/journal.ppat.1006296","article-title":"Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA","volume":"13","author":"Y Liu","year":"2017","journal-title":"PLoS Pathog"},{"issue":"2","key":"pcbi.1012615.ref069","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"L Belloni","year":"2012","journal-title":"J Clin Invest"},{"issue":"5","key":"pcbi.1012615.ref070","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11051349","article-title":"Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives.","volume":"11","author":"V Taverniti","year":"2022","journal-title":"J Clin Med."},{"issue":"11","key":"pcbi.1012615.ref071","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41575-022-00649-z","article-title":"A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook.","volume":"19","author":"A Kramvis","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3\u20134","key":"pcbi.1012615.ref072","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000360947","article-title":"Genotypes and genetic variability of hepatitis B virus.","volume":"57","author":"A Kramvis","year":"2014","journal-title":"Intervirology"},{"issue":"4","key":"pcbi.1012615.ref073","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jhep.2018.05.017","article-title":"New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings","volume":"69","author":"S Chevaliez","year":"2018","journal-title":"J Hepatol"},{"issue":"7","key":"pcbi.1012615.ref074","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/gut.2004.060327","article-title":"Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D","volume":"54","author":"A Erhardt","year":"2005","journal-title":"Gut"},{"issue":"22","key":"pcbi.1012615.ref075","doi-asserted-by":"crossref","first-page":"12083","DOI":"10.1128\/JVI.77.22.12083-12087.2003","article-title":"Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection","volume":"77","author":"CL Thio","year":"2003","journal-title":"J Virol"},{"issue":"7","key":"pcbi.1012615.ref076","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1053\/j.gastro.2005.03.009","article-title":"Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy","volume":"128","author":"JJ Sung","year":"2005","journal-title":"Gastroenterology"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1012615","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012615","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T18:45:03Z","timestamp":1737571503000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012615"}},"subtitle":[],"editor":[{"given":"Jessica M.","family":"Conway","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1012615","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pcbi.1012615","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]}}}